Merus NV gained accelerated U.S. FDA approval of Bizengri (zenocutuzumab) as the first and only targeted therapy indicated for NRG1-positive pancreatic adenocarcinoma and non-small-cell lung cancer ...
The growing demand for pelvic floor stimulation devices is driven by the rising incidence of urinary incontinence, ...